Venetoclax shows potential for R/R hairy cell leukemia

Published Date: 13 Mar 2023

Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

2.

Research identifies nearly 200 potential breast carcinogens in food packaging materials

3.

a brand-new generic therapy for different types of cancer.

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot